In Q2 2026, Deerfield Management held 63 positions worth $7.3B. They initiated 6 new positions and exited 613. Their largest holding was NUVL ($2.1B).
Frequently asked questions
What stocks did Deerfield Management own in Q2 2026?
Deerfield Management held 63 biotech stocks in their 13F portfolio in Q2 2026. Their top positions include NUVL, RVMD, PRAX, VTRS, UTHR. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deerfield Management's portfolio worth in Q2 2026?
Deerfield Management's tracked biotech portfolio was worth $7.3B across 63 positions, with total assets under management of approximately $16B. Portfolio values are based on 13F filings with the SEC.
What did Deerfield Management buy in Q2 2026?
Deerfield Management initiated 6 new positions in Q2 2026, including PBLS, AVLN, ODTX, ALMR, ADAG and 1 more. They also increased 15 existing positions.
What did Deerfield Management sell in Q2 2026?
Deerfield Management fully exited 613 positions in Q2 2026, including SMPL, TMUSL, VRSK, BBY, USAC and 608 more. They also trimmed 10 existing positions.
Is Deerfield Management a biotech fund?
Multi-strategy healthcare fund with one of the longest track records in the space. Deerfield invests across public equity, private equity, structured credit, and royalties in healthcare. Known for creative financing structures and deep industry relationships across pharma and biotech.
Want AI analysis, insider signals, and catalyst overlays for Deerfield Management?
View latest Deerfield Managementportfolio →